COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs

Nature Reviews Drug Discovery

Volumn 5, Issue 1, 2006, Pages 75-86

  Mitchell, Jane A ^a   Warner, Timothy D ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; DICLOFENAC; DIPYRONE; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MECLOFENAMIC ACID; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE A2; UNINDEXED DRUG; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EDEMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; GENETIC TRANSCRIPTION; HEART ARREST; HEART INFARCTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG EDEMA; LUNG EMBOLISM; META ANALYSIS; MORTALITY; MUSCULOSKELETAL DISEASE; NONHUMAN; OBSERVATIONAL METHOD; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT; ANIMAL; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS;

EID: 33644870565     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1929     Document Type: Review

References (128)

1. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231, 232-235 (1971).
2. Ferreira, S. H., Moncada, S. & Vane, J. R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol. 231, 237-239 (1971).
3. Smith, J. B. & Willis, A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol. 231, 235-237 (1971).
4. Vane, J. R., Bakhle, Y. S. & Botting, R. M. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120 (1998).
5. Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
6. DuBois, R. N. et al. Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073 (1998).
7. Fitzgerald, G. A. & Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442 (2001).
8. Flower, R. J. The development of COX2 inhibitors. Nature Rev. Drug Discov. 2, 179-191 (2003).
9. Warner, T. D. & Mitchell, J. A. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790-804 (2004).
10. Rosen, G. D., Birkenmeier, T. M., Raz, A. & Holtzman, M. J. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem. Biophys. Res. Commun. 164, 1358-1365 (1989).
11. Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 2692-2696 (1991).
12. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W. & Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266, 12866-12872 (1991).
13. Hla, T. & Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl Acad. Sci. USA 89, 7384-7388 (1992).
14. Masferrer, J. L., Seibert, K., Zweifel, B. & Needleman, P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl Acad. Sci. USA 89, 3917-3921 (1992).
15. O'Banion, M. K., Winn, V. D. & Young, D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA 89, 4888-4892 (1992).
16. Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J. & Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl Acad. Sci. US4 90, 11693-11697 (1993).
17. Mitchell, J. A. & Evans, T. W. Cyclooxygenase-2 as a therapeutic target. Inflamm. Res. 47 (Suppl. 2), S88-S92 (1998).
18. McAdam, B. F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA 96, 272-277 (1999).
19. Catella-Lawson, F. et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289, 735-741 (1999).
20. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
21. Horton, R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet 364, 1995-1996 (2004).
22. Topol, E. J. Failing the public health - rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351, 1707-1709 (2004).
23. Okie, S. Raising the safety bar - the FDA's coxib meeting. N. Engl. J. Med. 352, 1283-1285 (2005).
24. Antman, E. M., DeMets, D. & Loscalzo, J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112, 759-770 (2005).
25. Chandrasekharan, N. V. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 99, 13926-13931 (2002).
26. Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004).
27. Schade, S. et al. Diverse functional coupling of cyclooxygenase 1 and 2 with final prostanoid synthases in liver macrophages. Biochem. Pharmacol. 64, 1227-1232 (2002).
28. Snipes, J. A., Kis, B., Shelness, G. S., Hewett, J. A. & Busija, D. W. Cloning and characterization of cyclooxygenase-1b (putative COX-3) in rat. J. Pharmacol. Exp. Ther. 313, 668-676 (2005).
29. Warner, T. D. & Mitchell, J. A. Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? Proc. Natl Acad. Sci. USA 99, 13371-13373 (2002).
30. 2: Investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J. Pharmacol. Exp. Ther. 310, 642-647 (2004).
31. Kis, B., Snipes, J. A. & Busija, D. W. Acetaminophen and the COX-3 puzzle: Sorting out facts, fictions and uncertainties. J. Pharmacol. Exp. Ther. 315, 1-7 (2005).
32. Warner, T. D. et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl Acad. Sci. USA 96, 7563-7568 (1999).
33. Mitchell, J. A. & Warner, T. D. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 128, 1121-1132 (1999).
34. Perini, R., Fiorucci, S. & Wallace, J. L. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: A window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can. J. Gastroenterol. 18, 229-236 (2004).
35. Zimmermann, K. C., Sarbia, M., Schror, K. & Weber, A. A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol. 54, 536-540 (1998).
36. Wallace, J. L., McKnight, W., Reuter, B. K. & Vergnolle, N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119, 706-714 (2000).
37. Tanaka, A., Hase, S., Miyazawa, T., Ohno, R. & Takeuchi, K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: Relation to various pathogenic events. J. Pharmacol. Exp. Ther. 303, 1248-1254 (2002).
38. Langenbach, R. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483-492 (1995).
39. Sigthorsson, G. et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122, 1913-1923 (2002).
40. Vane, J. R. & Warner, T. D. Nomenclature for COX-2 inhibitors. Lancet 356, 1373-1374 (2000).
41. Moncada, S., Gryglewski, R., Bunting, S. & Vane, J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665 (1976).
42. Hamberg, M., Svensson, J. & Samuelsson, B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl Acad. Sci. USA 72, 2994-2998 (1975).
43. Roth, G. J., Machuga, E. T. & Ozols, J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 22, 4672-4675 (1983).
44. Patrono, C. Aspirin: New cardiovascular uses for an old drug. Am. J. Med. 110, 62S-65S (2001).
45. Pedersen, A. K. & Fitzgerald, G. A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311, 1206-1211 (1984).
46. Murata, T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682 (1997).
47. 2. Science 296, 539-541 (2002).
48. Rocca, B. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc. Natl Acad. Sci. USA 99, 7634-7639 (2002).
49. Tanaka, N., Sato, T., Fujita, H. & Morita, I. Constitutive expression and involvement of cyclooxygenase-2 in human megakaryocytopoiesis. Arterioscler. Thromb. Vasc. Biol. 24, 607-612 (2004).
50. Hasan, K., Warner, T. D., Vojnovic, I., Pepper, J. R. & Mitchell. Characterisation of cyclo-oxygenase activity in human megakaryocytes: relevance to platelet COX-2. British Pharmacological Society Meeting, London, UK, December, pA2 online. 2004;4:036P (2003).
51. Weber, A. A. et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: Induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br. J. Haematol. 117, 424-426 (2002).
52. Censarek, F. et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb. Haemost. 92, 925-928 (2004).
53. Patrignani, P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 110, 281-286 (2003).
54. Sanderson, S., Emery, J., Baglin, T. & Kinmonth, A. L. Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 142, 370-380 (2005).
55. Belton, O., Byrne, D., Kearney, D., Leahy, A. & Fitzgerald, D. J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 840-845 (2000).
56. Bishop-Bailey, D. et al. Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler. Thromb. Vasc. Biol. 17, 1644-1648 (1997).
57. Bishop-Bailey, D., Pepper, J. R., Larkin, S. W. & Mitchell, J. A. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: Role of endogenous prostanoids. Arterioscler. Thromb. Vasc. Biol. 18, 1655-1661 (1998).
58. Jimenez, R. et al. Role of Toll-like receptors 2 and 4 in the induction of cyclooxygenase-2 in vascular smooth muscle. Proc. Natl Acad. Sci. USA 102, 4637-4462 (2005).
59. Topper, J. N., Cai, J., Falb, D. & Gimbrone, M. A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. USA 93, 10417-10422 (1996).
60. Inoue, H. et al. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22, 1415-1420 (2002).
61. Doroudi, R., Gan, L. M., Selin Sjogren, L. & Jern, S. Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochem. Biophys. Res. Commun. 269, 257-264 (2000).
62. McCormick, S. M., Whitson, P. A., Wu, K. K. & McIntire, L. V. Shear stress differentially regulates PGHS-1 and PGHS-2 protein levels in human endothelial cells. Ann. Biomed. Eng. 28, 824-833 (2000).
63. Dancu, M. B., Berardi, D. E., Vanden Heuvel, J. P. & Tarbell, J. M. Asynchronous shear stress and circumferential strain reduces endothelial NO synthase and cyclooxygenase-2 but induces endothelin-1 gene expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 2088-2094 (2004).
64. Okahara, K., Sun, B. & Kambayashi, J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 1922-1926 (1998).
65. Wasserman, S. M. et al. Gene expression profile of human endothelial cells exposed to sustained fluid shear stress. Physiol. Genomics 12, 13-23 (2002).
66. McCormick, S. M. et al. DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc. Natl Acad. Sci. USA 98, 8955-8960 (2001).
67. Warabi, E. et al. Effect on endothelial cell gene expression of shear stress, oxygen concentration, and low-density lipoprotein as studied by a novel flow cell culture system. Free Radic. Biol. Med. 37, 682-694 (2004).
68. Chen, B. P. et al. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol. Genomics 7, 55-63 (2001).
69. Garcia-Cardena, G., Comander, J., Anderson, K. R., Blackman, B. R. & Gimbrone, M. A. Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc. Natl Acad. Sci. USA 98, 4478-4485 (2001).
70. Ohura, N. et al. Global analysis of shear stress-responsive genes in vascular endothelial cells. J. Atheroscler. Thromb. 10, 304-313 (2003).
71. Dai, G. et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc. Natl Acad. Sci. USA 101, 14871-14876 (2004).
72. Brooks, A. R., Lelkes, P. I. & Rubanyi, G. M. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol. Genomics 9, 27-41 (2002).
73. Yoshisue, H. et al. Large scale isolation of non-uniform shear stress-responsive genes from cultured human endothelial cells through the preparation of a subtracted cDNA library. Atherosclerosis 162, 323-334 (2002).
74. Resnick, N. & Gimbrone, M. A. Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J. 9, 874-882 (1995).
75. Dekker, R. J. et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 100, 1689-1698 (2002).
76. Baker, C. S. et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol. 19, 646-655 (1999).
77. Schonbeck, U., Sukhova, G. K., Graber, P., Coulter, S. & Libby, P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281-1291 (1999).
78. Stemme, V., Swedenborg, J., Claesson, H. & Hansson, G. K. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur. J. Vasc. Endovasc. Surg. 20, 146-152 (2000).
79. Lucas, R. et al. Expression of COX-1, but not COX-2 or COX-3; like immunoreactivity in human blood vessels and heart. British Pharmacological Society Meeting, London, UK, December, pA2online 2004;1(4):035P (2003).
80. Hamilton, L. C., Mitchell, J. A., Tomlinson, A. M. & Warner, T. D. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: Consequences for nonsteroidal anti-inflammatory drug efficacy. FASEB J. 13, 245-251 (1999).
81. Pratico, D., Tillmann, C., Zhang, Z. B., Li, H. & Fitzgerald, G. A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA 98, 3358-3363 (2001).
82. Csiszar, A. et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res. 90, 1159-1166 (2002).
83. Wong, E., Huang, J. Q., Tagari, P. & Riendeau, D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157, 393-402 (2001).
84. Rudic, R. D. et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ. Res. 96, 1240-1247 (2005).
85. Riendeau, D. et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 75, 1088-1095 (1997).
86. 2 synthases. Proc. Natl Acad. Sci. USA 99, 7130-7135 (2002).
87. Aronoff, D. M., Boutaud, O., Marnett, L. J. & Oates, J. A. Inhibition of prostaglandin H2 synthases by salicylate is dependent on the oxidative state of the enzymes. J. Pharmacol. Exp. Ther. 304, 589-595 (2003).
88. Lucas, R., Warner, T. D., Vojnovic, I. & Mitchell, J. A. Cellular mechanisms of acetaminophen: Role of cyclooxygenase. FASEB J. 19, 635-637 (2005).
89. Harris, R. C. et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94, 2504-2510 (1994).
90. Athirakul, K., Kim, H. S., Audoly L. P., Smithies, O. & Coffman, T. M. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int. 60, 2324-2329 (2001).
91. Epstein, M. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J. Hypertens. 20 (Suppl. 6), S17-S23 (2002).
92. Whelton, A. COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema. J. Hypertens. 20 (Suppl. 6), S31-S35 (2002).
93. 2 EP4 receptors. J. Am. Soc. Nephrol. 15, 1189-1198 (2004).
94. Singh, G. et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 30, 714-719 (2003).
95. Dilger, K. et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J. Clin. Pharmacol. 42, 985-994 (2002).
96. Schwartz, J. I. et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther. 65, 653-660 (1999).
97. Rossat, J., Maillard, M., Nussberger, J., Brunner, H. R. & Burnier, M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66, 76-84 (1999).
98. Patrignani, P., Capone, M. L. & Tacconelli, S. Clinical pharmacology of etoricoxib: A novel selective COX-2 inhibitor. Expert Opin. Pharmacother. 4, 265-284 (2003).
99. Alsalameh, S., Burian, M., Mahr, G., Woodcock, B. G. & Geisslinger, G. The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment. Pharmacol. Ther. 17, 489-501 (2003).
100. Zewde, T. & Mattson, D. L. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44, 424-428 (2004).
101. Whelton, A. et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch. Intern. Med. 160, 1465-1470 (2000).
102. Swan, S. K. et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 133, 1-9 (2000).
103. Whelton, A. et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 8, 85-95 (2001).
104. Whelton, A. et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 90, 959-963 (2002).
105. Mamdani, M. et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 363, 1751-1756 (2004).
106. Farkouh, M. E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 364, 675-684 (2004).
107. Day, R. Hypertension in the patient with arthritis: Have we been underestimating its significance? J. Rheumatol. 30, 642-645 (2003).
108. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528 (2000).
109. Silverstein, F. E. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: Ahe CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284, 1247-1255 (2000).
110. Schnitzer, T. J. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 364, 665-674 (2004).
111. Topol, E. J. & Falk, G. W. A coxib a day won't keep the doctor away. Lancet 364, 639-640 (2004).
112. Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E. & Mitchell, A. A. Are cyclooxygenase-2 inhibitors being taken only by those who need them? Arch. Intern. Med. 165, 1066-1067 (2005).
113. Graham, D. J. et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365, 475-481 (2005).
114. Solomon, D. H. et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109, 2068-2073 (2004).
115. Juni, P. et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364, 2021-2029 (2004).
116. Bresalier, R. S. et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
117. Solomon, S. D. et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl J Med. 352, 1071-1080 (2005).
118. Ott, E. et al. Efficacy and safety of the cyclo-oxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125, 1481-1492 (2003).
119. Nussmeier, N. A. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081-1091 (2005).
120. Reilly, I. A. & FitzGerald, G. A. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987).
121. Capone, M. L. et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471 (2004).
122. Shaya, F. T., Blume, S. W., Blanchette, C. M., Weir, M. R. & Mullins, C. D. Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population. Arch. Intern. Med. 165, 181-186 (2005).
123. Johnsen, S. P. et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch. Intern. Med. 165, 978-984 (2005).
124. Singh, G., Mithal, A. & Triadafilopoulos, G. Both selective COX-2 inhibitors and nonselective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: Selectivity is with the patient, not the drug class. Annu. Eur. Congress Rheumatol. Vienna, Austria, 8-11 June, Abstract OP0091 (2005).
125. Roth, S. H. Nonsteroidal antiinflammatory drug gastropathy: We started it, why don't we stop it? J. Rheumatol. 32, 1189-1191 (2005).
126. Olsen, N. J. Tailoring arthritis therapy in the wake of the NSAID crisis. N. Engl. J. Med. 352, 2578-2580 (2005).
127. Fischer, L. M., Schlienger, R. G., Matter, C. M., Jick, H. & Meier, C. R. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch. Intern. Med. 164, 2472-2476 (2004).
128. McKeever, T. M. et al. The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am. J. Respir. Crit. Care Med. 171, 966-971 (2005).